Cholecystitis [5-10] and other gallbladder toxicities (including biliary colic, cholelithiasis, gallbladder enlargement, and gallbladder wall thickening/edema [7,8,11,12]) have been reported in clinical trials investigating motesanib, an orally administered small-molecule antagonist of vascular endothelial growth factor receptors (VEGFRs) 1, 2, and 3; platelet-derived growth factor (PDGFR); and Kit for the treatment of advanced solid tumors. Here, PDGFRB is linked to Cholecystitis.